Repurposing approved non-antibiotic drugs for their anti-tubercular potential

Raghuveer Varma Pemmadi

Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapur, Andhra Pradesh, India, 515721.

Ranjan Nanda

Translational Health, International Center for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India, 110 067.

Abstract

The prevalence of antimicrobial resistance (AMR) among pathogenic microbes is on an all time high and the current scenario is quite devastating. Mycobacterium tuberculosis, the culprit for causing tuberculosis (TB) has evolved efficient mechanisms to such an extent that, in certain cases, it is resistant to most of the available anti-TB drugs resulting in multiple/ extensively/ totally drug resistant (M/E/TDR) forms of TB. Treating these patients requires novel drugs and repurposing the existing drugs approved for other conditions may provide useful hits. In this project, we aim to screen a small library of selected structurally diverse groups of already approved drugs against laboratory strains to identify hits for further validation.

Keywords: Anti-microbial resistance, Mycobacterium tuberculosis, Non-antibiotic drugs, Repurposing.